JBN Biotech ApS: Financial statements 2024
CVR: 40685693
Source: annual report 2024, Danish Business Authority
01/07/2023 – 30/06/2024
JBN Biotech ApS (CVR 40685693) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -20,188 and a net result of DKK -263,330 compared with DKK -184,457 the year before. Equity in the 2024 report amounted to DKK 35,164,111. The solvency ratio was 74.9%.
- Gross Profit
- DKK -20,188
- Profit/Loss
- DKK -263,330
- Equity
- DKK 35,164,111
- Total Assets
- DKK 46,968,168
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | -20 t. | -263 t. | 35.2 mio. | 0 |
| 2023 | - | -25 t. | -184 t. | 35.4 mio. | 0 |
| 2022 | - | -16 t. | 31.9 mio. | 35.6 mio. | 0 |
| 2021 | - | -16 t. | 4.3 mio. | 3.7 mio. | 0 |
| 2020 | - | -27 t. | -646 t. | -606 t. | 0 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningAbout JBN Biotech ApS
JBN Biotech ApS is a Danish company of the type Anpartsselskab based in Hellerup, founded in 2019. The company is registered under the industry Anden finansiel formidling i.a.n.. The management consists of Jens Bredal Nielsen. The company is owned by Jens Bredal Nielsen. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -22,188 and a net result of DKK -222,807 compared with DKK -263,330 the year before. Equity in the 2025 report amounted to DKK 34,941,304.